ClinicalTrials.gg
Status unknownNCT05687331CASHUpdated Jan 18, 2023

Changes in the Immunomodulatory Properties of Adipose Stromal Cells Due to Hemarthrosis After Knee Injury

An observational study in Post-Traumatic Osteoarthritis of Knee, Knee Injuries and Hemarthrosis, sponsored by Radboud University Medical Center. Status unknown at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Radboud University Medical Center · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to gain insight in the natural course of pro-inflammatory factors and hemarthrosis in patients older than 18 with a recent knee trauma. The main question[s] it aims to answer are:

  • What is the natural course of pro-inflammatory factors and hemarthrosis in knee trauma?
  • What are the effects of inflammation and hemarthrosis on the anti-inflammatory potential of ASC's in order to better determine eligible patients and circumstances for ASC's therapy?

Participants will:

  • undergo blood withdrawal
  • undergo knee arthrocentesis for synovial fluid sample collection
  • physical examination
  • fill out a questionnaire on knee complaints
Read the detailed description

Recent studies have found an amelioration of post-traumatic osteoarthritis by the use of adipose-derived stromal cells (ASC's) in an experimental animal model. This amelioration was only seen under inflammatory conditions. The presence of hemarthrosis has not been taken into account in the before mentioned animal model, and might have cytotoxic effects on ASC's and aggravate the inflammatory response. The objective of this study is to gain insight in the natural course of pro-inflammatory factors and hemarthrosis and its effects on the anti-inflammatory potential of ASC's in order to better determine eligible patients and circumstances for ASC's therapy.

Therefore the investigators designed a pilot study with exploratory analyses in and with synovial fluid in a longitudinal cohort.

Our study population will consist of 20 patients, older than 18 years, who sustained a recent knee trauma and are presented to the emergency department.The investigators will gather synovial fluid and blood samples for laboratory analysis perform and physical examination and provide questionnaires for clinical follow-up.

The main study endpoint are the anti-inflammatory capacities of ASC's in synovial fluid that contains blood as a result of hemarthrosis after knee injury.

02

Conditions studied

  • Post-Traumatic Osteoarthritis of Knee
  • Knee Injuries
  • Hemarthrosis
03

In context

Knee Injuries

267 studies on the registry are indexed under Knee Injuries; 59 are open to participants now.

This study's planned enrollment of 20 is below the median of 82 across 79 observational studies indexed under Knee Injuries.

Browse Knee Injuries studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 136 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adult patients who are presented at the emergency department of the CWZ hospital because of a recent distortion of the knee.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recently suffered an injury of the index knee (rotational or hyperextension)
  • A swollen joint
  • Inability to mobilise

Exclusion criteria

Exclusion Criteria:

  • Patients with an active inflammatory or infectious comorbid disease (including rheumatic diseases)
  • Patients using systemic medication
  • Patients with a for undergoing a MRI-scan (non-compatible implants or claustrophobia for example)
  • Patients with knee prosthesis
  • Patients with coagulation disorders
  • Patients with a history of a cruciate ligament or meniscal injury of the index knee
  • Patients with a tibiofemoral fracture of the index knee due to current distortion
  • In case the inclusion of the required amount of patient is reached in one the patient groups, additional patients belonging in the same patient group will not be included in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with hemarthrosis

    10 patients that sustained a knee trauma and have hemarthrosis during knee arthrocentesis (red color of the synovial fluid)

    Procedure: knee arthrocentesis · Procedure: venipuncture · Diagnostic Test: MRI-scan · Diagnostic Test: Physical examination · Other: KOOS questionnaire

  • Patients without hemarthrosis

    10 patients that sustained a knee trauma and do not have hemarthrosis during knee arthrocentesis (yellow color of the synovial fluid)

    Procedure: knee arthrocentesis · Procedure: venipuncture · Diagnostic Test: MRI-scan · Diagnostic Test: Physical examination · Other: KOOS questionnaire

Interventions

  • Procedureknee arthrocentesis

    arthrocentesis of the knee joint to gather a synovial fluid sample

  • Procedurevenipuncture

    Peripheral venipuncture to gather a blood sample

    Also known as: blood draw

  • Diagnostic testMRI-scan

    MRI-scan of the knee

  • Diagnostic testPhysical examination

    Physical examination of the injured knee

  • OtherKOOS questionnaire

    KOOS questionnaire of the injured knee

06

What researchers measure

Primary outcomes

  1. Synovial fluid analysis

    Analysis of changes in pro-inflammatory factors, erythrocytes (as measurement for hemarthrosis)

    Time frame: Samples are taken at week 1, week 2, week 4, week 6 and week 8 after trauma

Secondary outcomes

  1. co-culture of synovial fluid with adipose stromal cells

    Assessment of changes in cytotoxity of hemarthrosis in synovial fluid on adipose stromal cells

    Time frame: samples are taken at week 1, week 2, week 4, week 6 and week 8 after trauma

  2. MRI-imaging

    MRI-images to determine post-traumatic changes in the articulate cartilage

    Time frame: At inclusion and 1 year after trauma

  3. Physical examination

    Assessment of changes in swelling, warmth and appearance of the skin

    Time frame: Physical examination at week 1, week 2, week 4, week 6 and week 8 after trauma

  4. Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire

    Assessment changes of knee complaints by using the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, with minimum score of 0 and a maximum score of 100 and a higher score meaning a better outcome.

    Time frame: Questionnaires are taken at week 1, week 2, week 4, week 6 and week 8 after trauma

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Riordan EA, Little C, Hunter D. Pathogenesis of post-traumatic OA with a view to intervention. Best Pract Res Clin Rheumatol. 2014 Feb;28(1):17-30. doi: 10.1016/j.berh.2014.02.001. PubMed 24792943 ↗
  • Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007 Oct;35(10):1756-69. doi: 10.1177/0363546507307396. Epub 2007 Aug 29. PubMed 17761605 ↗
  • Luc B, Gribble PA, Pietrosimone BG. Osteoarthritis prevalence following anterior cruciate ligament reconstruction: a systematic review and numbers-needed-to-treat analysis. J Athl Train. 2014 Nov-Dec;49(6):806-19. doi: 10.4085/1062-6050-49.3.35. PubMed 25232663 ↗
  • Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage. 2005 May;13(5):361-7. doi: 10.1016/j.joca.2005.01.005. PubMed 15882559 ↗
  • Pulles AE, Mastbergen SC, Schutgens RE, Lafeber FP, van Vulpen LF. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res. 2017 Jan;115:192-199. doi: 10.1016/j.phrs.2016.11.032. Epub 2016 Nov 24. PubMed 27890816 ↗
  • Gupte C, St Mart JP. The acute swollen knee: diagnosis and management. J R Soc Med. 2013 Jul;106(7):259-68. doi: 10.1177/0141076813482831. PubMed 23821708 ↗
  • Wang Y, Shimmin A, Ghosh P, Marks P, Linklater J, Connell D, Hall S, Skerrett D, Itescu S, Cicuttini FM. Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial. Arthritis Res Ther. 2017 Aug 2;19(1):180. doi: 10.1186/s13075-017-1391-0. PubMed 28768528 ↗
  • ter Huurne M, Schelbergen R, Blattes R, Blom A, de Munter W, Grevers LC, Jeanson J, Noel D, Casteilla L, Jorgensen C, van den Berg W, van Lent PL. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum. 2012 Nov;64(11):3604-13. doi: 10.1002/art.34626. PubMed 22961401 ↗
  • Schelbergen RF, van Dalen S, ter Huurne M, Roth J, Vogl T, Noel D, Jorgensen C, van den Berg WB, van de Loo FA, Blom AB, van Lent PL. Treatment efficacy of adipose-derived stem cells in experimental osteoarthritis is driven by high synovial activation and reflected by S100A8/A9 serum levels. Osteoarthritis Cartilage. 2014 Aug;22(8):1158-66. doi: 10.1016/j.joca.2014.05.022. Epub 2014 Jun 10. PubMed 24928317 ↗
  • Pers YM, Rackwitz L, Ferreira R, Pullig O, Delfour C, Barry F, Sensebe L, Casteilla L, Fleury S, Bourin P, Noel D, Canovas F, Cyteval C, Lisignoli G, Schrauth J, Haddad D, Domergue S, Noeth U, Jorgensen C; ADIPOA Consortium. Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. Stem Cells Transl Med. 2016 Jul;5(7):847-56. doi: 10.5966/sctm.2015-0245. Epub 2016 May 23. PubMed 27217345 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05687331
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Apr 5, 2022
Primary completion
Apr 1, 2023 (estimated)
Completion
Apr 1, 2024 (estimated)
Last update
Jan 18, 2023

Study contacts

Bob Evers, Drs/Msc
Contact
Bob.J.Evers@radboudumc.nl
06-29630837
Rogier Thurlings, Dr/PhD
Contact
rogier.thurlings@radboudumc.nl
0629652920

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion